[{"id":"8fe85d39-9953-455f-b568-6b583ec5f7cb","acronym":"BEVERLY","url":"https://clinicaltrials.gov/study/NCT02633189","created_at":"2021-01-18T12:48:29.284Z","updated_at":"2024-07-02T16:35:52.564Z","phase":"Phase 3","brief_title":"Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer","source_id_and_acronym":"NCT02633189 - BEVERLY","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-03-24"},{"id":"68799ef7-4ca6-42fa-afc7-d1b81bc51e00","acronym":"CAPLAND","url":"https://clinicaltrials.gov/study/NCT04811001","created_at":"2021-03-23T11:52:10.171Z","updated_at":"2024-07-02T16:35:55.090Z","phase":"Phase 2","brief_title":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","source_id_and_acronym":"NCT04811001 - CAPLAND","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C","tags":["EGFR • HER-2 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/12/2020","start_date":" 06/12/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-21"},{"id":"688647c6-52cf-4685-a109-76fbfbb4afb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804100","created_at":"2021-01-18T13:45:32.383Z","updated_at":"2024-07-02T16:37:28.068Z","phase":"","brief_title":"Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients","source_id_and_acronym":"NCT02804100","lead_sponsor":"Wenzhou Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719A • EGFR G719S • EGFR G719C • EGFR exon 19 insertion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719A • EGFR G719S • EGFR G719C • EGFR exon 19 insertion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2016-11-01"}]